Cargando…

Survival times are similar among patients with peritoneal, hematogenous, and nodal recurrences after curative resections for gastric cancer

BACKGROUND: The three dominant recurrence patterns of gastric cancer are peritoneal, hematogenous, and nodal recurrence. Correlation between initial recurrence site and prognosis is poorly understood, particularly after standardization of postoperative S‐1 adjuvant chemotherapy. METHODS: We analyzed...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawaki, Koichi, Kanda, Mitsuro, Ito, Seiji, Mochizuki, Yoshinari, Teramoto, Hitoshi, Ishigure, Kiyoshi, Murai, Toshifumi, Asada, Takahiro, Ishiyama, Akiharu, Matsushita, Hidenobu, Tanaka, Chie, Kobayashi, Daisuke, Fujiwara, Michitaka, Murotani, Kenta, Kodera, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402812/
https://www.ncbi.nlm.nih.gov/pubmed/32515147
http://dx.doi.org/10.1002/cam4.3208
Descripción
Sumario:BACKGROUND: The three dominant recurrence patterns of gastric cancer are peritoneal, hematogenous, and nodal recurrence. Correlation between initial recurrence site and prognosis is poorly understood, particularly after standardization of postoperative S‐1 adjuvant chemotherapy. METHODS: We analyzed a multi‐institutional database of 3484 patients who underwent gastrectomy for gastric cancer between 2010 and 2014. Patients who experienced recurrences after curative gastrectomy classified into peritoneal, hematogenous, or nodal recurrence groups, according to their initial recurrence sites, and their prognoses were compared. RESULTS: We included 313 patients in the analysis, of whom 190 patients (63%) were treated with postoperative adjuvant chemotherapy. Pathological disease states were stage I: n = 20 (6%), stage II: n = 62 (20%), and stage III: n = 231 (74%). Patients were categorized into groups by peritoneal (n = 127), hematogenous (n = 123), and nodal (n = 63) recurrence. The peritoneal recurrence group tended to have longer recurrence‐free survival, but shorter post‐recurrence survival, than the other two groups. Median disease‐specific survival after curative resection by group were peritoneal: 25.8 months, hematogenous: 29.0 months, and nodal: 27.8 months (peritoneal vs hematogenous, P = .152; hematogenous vs nodal, P = .955; peritoneal vs nodal, P = .213). CONCLUSIONS: Prognoses after curative resection for gastric cancer were similar among patients with peritoneal, hematogenous, or nodal recurrences.